Masanori Terashima

Shizuoka Cancer Center

Papers

24

Total Citations

797

H-Index

14

About

Masanori Terashima is a leading surgical oncologist whose career has been defined by his pioneering contributions to robotic and minimally invasive surgery for gastric cancer. His research has systematically advanced the clinical adoption of robotic gastrectomy, from early feasibility studies to large-scale multi-institutional trials. His 2018 prospective multi-institutional study demonstrating the clinical advantages of robotic gastrectomy for stage I/II gastric cancer (231 citations) stands as a landmark contribution to the field, providing the rigorous evidence needed to justify broader implementation. Terashima has progressively built the evidence base for robotic surgery through phase II trials, comparative studies against laparoscopic approaches, and nationwide registry analyses examining safe adoption under Japan's universal health insurance system. His body of work, spanning systematic reviews, propensity score-matched analyses, and randomized controlled trial designs—including the ongoing JCOG1907 MONA LISA study—reflects a commitment to elevating surgical standards through high-quality evidence. With hundreds of citations across his major publications, Terashima's research has meaningfully shaped international surgical guidelines and continues to influence how surgeons and healthcare systems approach the treatment of gastric cancer worldwide.

Research Focus

Key Achievements

14
H-Index
24
Papers
797
Total Citations
33
Avg Citations/Paper
🏆 Most Cited Paper
Clinical advantages of robotic gastrectomy for clinical stage I/II gastric cancer: a multi-institutional prospective single-arm study
231 citations · 2018
📈 Most Prolific Year: 2021 (4 Papers)
🤝 Key Collaborators: 82
🏛 Institutions: Shizuoka Cancer Center

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago